NOVARTIS AG-SPONSORED ADR (NVS)
US66987V1098 - ADR
February 2025 Options Now Available For Novartis (NVS)
For those who appreciate value investing, NYSE:NVS is a compelling option with its solid fundamentals.
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Some 330 jobs hit as Novartis closes Morphosys, WiWo reports
Swiss pharmaceutical group Novartis is winding up the German biotech company Morphosys, which it acquired at the beginning of the year, German news outlet WirtschaftsWoche reported on Thursday, saying 330 jobs would be affected. "In November 2024, we made the decision to close the Morphosys sites in Germany and the U.S. by the end of 2025 and to integrate all portfolio activities into Novartis," WiWo cited Novartis as saying. Novartis did not immediately respond to an emailed request for comment from Reuters.
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
Why the dividend investor may take a look at NYSE:NVS.
Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) qualifies as a good dividend investing stock.
The Zacks Analyst Blog Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI Technology
Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI Technology are included in this Analyst Blog.
Top Stock Reports for Mastercard, Procter & Gamble & Novartis
Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), The Procter & Gamble Company (PG) and Novartis AG (NVS), as well as two micro-cap stocks, IDT Corporation (IDT) and GSI Technology, Inc. (GSIT).
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug
The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval.
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 therapies.
European Stocks Gain, CAC Rises Ahead of No-Confidence Vote
(Bloomberg) -- European stocks advanced for a fifth consecutive session as German shares hit a fresh record. Investors were watching the no-confidence vote taking place in France. Most Read from BloombergAs Wars Rage, Cities Face a Dark New Era of Urban DestructionRiyadh Metro Partially Opens in Bid to Ease City’s Traffic JamsThe Stoxx Europe 600 Index rose 0.4% by the close, with retail stocks leading the gains. Spanish retailer Inditex SA jumped to a record high ahead of earnings and Zalando S
Novartis Enters Oversold Territory (NVS)
Why Novartis (NVS) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.
PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy
Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion.
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
The deal focuses on the company's treatment for Huntington's disease.
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis...
The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis
Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis are included in this Analyst Blog.
2 Dividend Stocks to Buy and Hold Forever
EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer
Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.